Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2019 · 10-Q
Revenue$26.02M$26.02M+71.2% vs Q3 2018 Net Income-$106.17M-$106.17MN/M vs Q3 2018 EPS Diluted-$1.81-$1.81N/M vs Q3 2018 Operating Income-$109,060,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$87,627,000N/M Margins · derivedOperating margin-419.1%+233.4 pt vs Q3 2018
Net margin-408.0%+214.9 pt vs Q3 2018
ended Sep 30, 2019 · filed Oct 31, 2019 · 31 d after period end